Festival of Pharma empowers GVK BIO to meet with smaller companies that don’t normally attend events
Ahead of the world’s largest ever virtual pharma expo – the CPHI Festival of Pharma – Informa Markets spoke with Ramesh Subramanian, Chief Commercial Officer at GVK BIO on how they are preparing for the event.
Can you tell me about your company and what you do?
GVK BIO is a CRDO – a contract research & development organisation – we help our customers ‘Accelerate R&D’. We support our partners through seven global sites, and a committed, customer focused staff of 3000. Our approach is to help customers accelerate programs into the clinic and then, advance them through commercialisation and into medicines.
What do you hope to achieve from the CPHI Festival of Pharma?
CPHI has been one of GVK BIO’s top global meetings helping us meet with our key current partners and also develop new ones, as well as providing ‘a pulse of the industry’ to help identify trends and direction. We use our discussions here with customers to recognize their future needs and align GVK BIO’s strategy. So we are looking forward to achieving the same goals at this year’s virtual event too.
What type of customer are you trying to meet with?
We target two broad segments: the big pharma companies looking for providers like ourselves to expedite multiple development programs across a number of targets, and biotech customers that have a core program or two to support. The strength of CPHI is that it allows biotechs to access several suppliers in one place. It enables them to meet and assess a number of suitable partners at one location, have detailed discussions, and potentially choose the partner that they are most comfortable with.
What are you going to be talking about with customers this week?
Our strategy is to align our investments and strategy with our customers future needs, and the ongoing pandemic has demonstrated the importance of external partnerships to advance programs. GVK has seen a lot of customer interest in some of our recent investments, particularly in high potency (we can now make up to 1 ug/L) and continuous flow technologies. In discovery, we are expanding our footprint in chemistry and biology. In fact, the past year has been stellar in terms of capital raised for the industry, and there has been an increased demand for outsourcing services. The other major trend that is accelerating quickly – and actually predates COVID – is the ‘China +1’ strategy, where customers want to geo-diversify their supply chain, and GVK has been a major beneficiary of this.
Finally, even as we grow our legacy small molecule business, the fastest growing segment for us is our biologics business, base near San Francisco. We expect biologics development, and cell culture manufacturing to be a key growth driver for us, we are now looking to advance this quickly. So you can expect an announcement from us in the near future on this.
Are there any sessions or any elements you’re particularly looking for in the next two weeks?
One of the nice things about this year is that more people are able to take part in the event, as it is digital. We have our teams looking at the sessions to identify what fits best for them and how they can implement it into their personal learning objectives.
Are there any categories you entered for this year’s CPHI Awards? If so, tell us a bit about your entry.
We love the awards and are very honoured to be finalists in the Supply Chain Category. Supply Chain, with COVID, has been a big area of interest for our customers and we are pleased to see our efforts to minimize disruption and ensure supply chain continuity and robustness have been recognized.
Do you think over the next few years we’re going to see more digital events?
One thing I will say is because it’s virtual, it allows us to have a lot more productive meetings and invite more people – as there are no travel budget concerns. The interesting aspect is that we anticipate many customers may wait until the very last minute to confirm attendance. It also means you can have a far wider geographic spread of customers – and we are looking forward to meeting with potential new business leads that would not necessarily, ordinarily, been able to attend a CPHI in person.
What are you looking forward to at next year’s CPHI?
We look forward, like everyone else, to the world reopening next year, and I think people have started to fully appreciate just a what a great event CPHI Worldwide is. Now that we are unable to attend in person, we can’t wait to be back with the community again next year. This is an amazing industry - the only one whereby doing well, you can also directly impact human health - and CPHI is an integral component of its ecosystem. We wish the event every success.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance